Cargando…

Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant

OBJECTIVE: To summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment. METHODS: From December 10, 2022, to January 20, 2023, the clinical data of children with hematological d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yixian, Liu, Yong, Wen, Luping, Chen, Hui, Wang, Wenqing, Tian, Mengyao, Cheng, Yucai, Xue, Hongman, Chen, Chun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167044/ https://www.ncbi.nlm.nih.gov/pubmed/37181421 http://dx.doi.org/10.3389/fped.2023.1160929

Ejemplares similares

The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial
por: Zhong, Weijie, et al.
Publicado: (2022)

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients
por: Weng, Chengzhao, et al.
Publicado: (2023)

The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2
por: Park, Hanul, et al.
Publicado: (2022)

High number of seizures and unconsciousness in patients with SARS-CoV-2 omicron variants: a retrospective study
por: Tokuyama, Kishin, et al.
Publicado: (2023)

Clinical Profile and Outcome of Hospitalized Confirmed Cases of Omicron Variant of SARS-CoV-2 Among Children in Pune, India
por: Kinikar, Aarti A, et al.
Publicado: (2022)

SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant
por: Taytard, Jessica, et al.
Publicado: (2022)

Case report: Acute hepatitis in neonates with COVID-19 during the Omicron SARS-CoV-2 variant wave: a report of four cases
por: Wang, Jing, et al.
Publicado: (2023)

Evaluation of febrile seizures in children infected with SARS-CoV-2 Omicron variant in Yunnan, China: a multi-center, retrospective observational study
por: Liu, Hai-feng, et al.
Publicado: (2023)

Serum neutralizing capacity and T-cell response against the omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection
por: Seidel, Alina, et al.
Publicado: (2023)

Clinical characteristics of children with omicron SARS-CoV-2 infection in Changchun, China from march to april 2022: A retrospective study
por: Li, Yan-chun, et al.
Publicado: (2022)

The Omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children
por: Setiabudi, Djatnika, et al.
Publicado: (2022)

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)

Covid-19 omicron variant infection in neonates of Guangdong province-a report of 52 cases
por: Yang, Yi-Kang, et al.
Publicado: (2023)

The Path to Paxlovid
por: Halford, Bethany
Publicado: (2022)

Dynamic disease manifestations among individuals infected with SARS-CoV-2 Omicron variant
por: Wang, Peiqin, et al.
Publicado: (2023)

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection
por: Sun, Fangfang, et al.
Publicado: (2022)

Mathematical model of SARS-CoV-2 immunity predicts Paxlovid rebound
por: Ranard, Benjamin L., et al.
Publicado: (2023)

Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
por: Liu, Jiao, et al.
Publicado: (2023)

SARS-CoV-2 omicron variant: the black swan of microbiology
por: Cheng, Zhangkai J., et al.
Publicado: (2022)

Prevalence and associating factors of long COVID in pediatric patients during the Delta and the Omicron variants
por: Lokanuwatsatien, Tananya, et al.
Publicado: (2023)

Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
por: Blennow, Ola, et al.
Publicado: (2022)

Early report on the severity of COVID‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant
por: Ullrich, Fabian, et al.
Publicado: (2022)

In Silico Evaluation of Paxlovid’s Pharmacometrics for SARS-CoV-2: A Multiscale Approach
por: Bartha, Ferenc A., et al.
Publicado: (2022)

Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
por: Niraj, Niraj, et al.
Publicado: (2022)

Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies
por: Taenaka, Ryutaro, et al.
Publicado: (2022)

Pediatric infection with the Omicron variant increases the risks of febrile seizures among COVID-19 infected children
por: Mohamed, Zakaria Ahmed, et al.
Publicado: (2023)

Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022
por: Kim, Jong Mu, et al.
Publicado: (2023)

Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection
por: Fishbane, Steven, et al.
Publicado: (2022)

The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study
por: Yan, Gangfeng, et al.
Publicado: (2022)

Comparison of Hematological and Biochemical Parameters of SARS-CoV-2-Positive and -Negative Neonates of COVID-19 Mothers in a COVID-19 Hospital, Odisha State
por: Panda, Santosh K, et al.
Publicado: (2022)

Editorial: Case reports in pediatric hematology and hematological malignancies 2022
por: Santos, Paulo S. S., et al.
Publicado: (2023)

Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023)

Febrile seizure in children with COVID-19 during the Omicron wave
por: Xu, Pu, et al.
Publicado: (2023)

Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
por: Lee, Richard Kuan-Lin, et al.
Publicado: (2022)

The future of Paxlovid for COVID-19
por: Burki, Talha
Publicado: (2022)

Ranolazine Toxicity Secondary to Paxlovid
por: Casey, Bradley, et al.
Publicado: (2023)

Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report
por: Zhang, Liulu, et al.
Publicado: (2022)

Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient
por: Shah, Aaisha, et al.
Publicado: (2022)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pt2vu458uf4lshj7ebuuatte5r